Difference between revisions of "ALK translocation renal cell carcinoma"
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
DDx: | DDx: | ||
*[[Papillary renal cell carcinoma]] | *[[Papillary renal cell carcinoma]] - especially "type 2".<ref name=pmid24255633/> | ||
*[[Unclassified renal cell carcinoma]] | *[[Unclassified renal cell carcinoma]] | ||
*[[Renal medullary carcinoma]]. | *[[Renal medullary carcinoma]]. | ||
Revision as of 14:06, 4 April 2019
ALK translocation renal cell carcinoma is a proposed entity within the Vancouver modification of the 2004 WHO classification of renal neoplasia.[1]
General
- Extremely rare - 1 in 829 consecutively screened patients.[2]
- May be related to renal medullary carcinoma which is reported to have an ALK rearrangement - t(2;10)(p23;q22).[3]
- May respond to ALK inhibitors, e.g. Alectinib.[4]
Microscopic
Features:
- Mix of morphologies - including rhabdoid change, sarcomatoid change, "unclassified renal cell carcinoma", papillary renal cell carcinoma.
DDx:
- Papillary renal cell carcinoma - especially "type 2".[2]
- Unclassified renal cell carcinoma
- Renal medullary carcinoma.
IHC
Features:[5]
- ALK +ve.
- PAX8 +ve.
- Vimentin +ve (diffuse).
- CK7 +ve (focal).
- SMARCB1 +ve.[citation needed]
See also
References
- ↑ Srigley, JR.; Delahunt, B.; Eble, JN.; Egevad, L.; Epstein, JI.; Grignon, D.; Hes, O.; Moch, H. et al. (Oct 2013). "The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.". Am J Surg Pathol 37 (10): 1469-89. doi:10.1097/PAS.0b013e318299f2d1. PMID 24025519.
- ↑ 2.0 2.1 Lee, C.; Park, JW.; Suh, JH.; Nam, KH.; Moon, KC. (Oct 2013). "ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients.". Korean J Pathol 47 (5): 452-7. doi:10.4132/KoreanJPathol.2013.47.5.452. PMID 24255633.
- ↑ Mariño-Enríquez, A.; Ou, WB.; Weldon, CB.; Fletcher, JA.; Pérez-Atayde, AR. (Mar 2011). "ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.". Genes Chromosomes Cancer 50 (3): 146-53. doi:10.1002/gcc.20839. PMID 21213368.
- ↑ Pal, SK.; Bergerot, P.; Dizman, N.; Bergerot, C.; Adashek, J.; Madison, R.; Chung, JH.; Ali, SM. et al. (07 2018). "Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.". Eur Urol 74 (1): 124-128. doi:10.1016/j.eururo.2018.03.032. PMID 29685646.
- ↑ Jeanneau, M.; Gregoire, V.; Desplechain, C.; Escande, F.; Tica, DP.; Aubert, S.; Leroy, X. (Nov 2016). "ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult.". Pathol Res Pract 212 (11): 1064-1066. doi:10.1016/j.prp.2016.07.015. PMID 27554841.